04 June 2001 00:00 [Source: ICB Americas]Ineos is planning to become a larger force in the supply of CFC-free fluorochemical medical propellants after starting production of HFA-227ea (heptafluoropropane) to cGMP standards.The company, which last year took over ICI's fluorochemicals business, has shipped its first bulk supplies of 227ea propellant to Europe from a joint venture plant with Great Lakes at El Dorado, Ark.Ineos Fluor believes that cGMP production of 227ea will open opportunities in providing propellants for new treatments delivered through the lung."The availability of this additional propellant represents the next step in our strategy to serve a broader cross-section of the life sciences industry," says Tim Noakes, Ineos Fluor's product manager for medical propellants. Ineos Fluor's 227ea and its existing HFC-134a (tetrafluoroethane) is being provided for metered dose inhalers (MDIs) for the treatment of asthma and other lung diseases. With nearly a quarter of the world's MDIs currently using Ineos' 134a, the company is a leading global supplier of CFC-free medical propellants with its main competitors being Solvay and DuPont.In the 227ea market, it competes with Solvay for a share of propellants sales to the new sector of inhaled insulins for diabetes treatment.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Asian Chemical Connections